BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Concentrations

Concentrations

12 Months Ended

Dec. 31, 2016

Risks And Uncertainties [Abstract]

Concentrations

NOTE 9 — CONCENTRATIONS

Revenue from the Company’s products for the years ended December 31, 2016, 2015 and 2014 are as follows:

	Years Ended December 31,
	2016			2015			2014
Laser systems		67.9	%		67.5	%		61.9	%
Imaging systems		5.9	%		4.6	%		9.0	%
Consumables and other		13.3	%		14.2	%		13.7	%
Services		12.6	%		13.3	%		15.1	%
License fees and royalties		0.3	%		0.4	%		0.3	%
Total revenue		100.0	%		100.0	%		100.0	%

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

No individual customer represented more than 10% of the Company’s accounts receivable at December 31, 2016 and 2015.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations and financial condition.